MHNCS 2022 - 2022 Multidisciplinary Head and Neck Cancers Symposium
Feb 24 - Feb 26, 2022 | PhoenixAZUS
LARVOL is not affiliated with 2022 Multidisciplinary Head and Neck Cancers Symposium and all trademarks, logos, and brand names are property of their respective owners
Showing 24 abstracts linked to Trials
Randomized Phase III, Double Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma
Immune and Tumor Genome Signatures Associated With Response to Radiotherapy and Chk-1 Inhibition in a Phase 1b Clinical Trial for Patients With Head and Neck Squamous Cell Carcinoma
Acute Toxicity Profile and Early Efficacy Results of De-Escalated, Risk-Directed Post-Operative Adjuvant Therapy for Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma: A Phase 2 Trial
Analysis of Outcomes by Smoking Status in a Phase III Trial of De-Escalated Adjuvant Chemoradiation Therapy in Human Papillomavirus (HPV(+)) Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Evaluation of Cell-Free HPV DNA in Patients With HPV-Associated Oropharyngeal Cancer Treated With Induction Chemotherapy and Response-Adaptive Therapy
Preliminary Safety of PDS0101 (Versamune +HPVmix) and Pembrolizumab Combination Therapy in Subjects With Recurrent/Metastatic Human Papillomavirus-16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
EVOLVE: Evaluating the Safety of De-escalated Head and Neck Irradiation in HPV Positive Oropharynx Cancer in Non/Minimal Smokers.
DEHART: Dose-Escalated Hypofractionated Adaptive Radiation Therapy With Atezolizumab for Head and Neck Cancers
Phase 1/2 Study of Pepinemab in Combination With Pembrolizumab as First-Line Treatment of Advanced, Recurrent or Metastatic Head and Neck Cancer (KEYNOTE B84)
A Phase 0 Master Protocol Utilizing a Novel Intratumoral Microdosing Approach for Simultaneously Evaluating Multiple Drugs and Drug Combinations in Patients With Solid Tumors
Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
Marrow Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study Protocol for a Phase I Dose Escalation Trial of Patients With Xerostomia After Radiation Therapy for Head and Neck Cancer
Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Single-Arm Pilot Study
Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy